CAS 109351-34-0

(R)-Terazosin

Formula: C₁₉H₂₅N₅O₄

Synonyms:

• Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, (R)-
• Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[[(2R)-tetrahydro-2-furanyl]carbonyl]- (9CI)
• (R)-(4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone
• (R)-Terazosin
• Terazosin-002-R
• Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl][(2R)-tetrahydro-2-furanyl]-

(R)-Terazosin

CAS: 109351-34-0

R-Terazosin is the active R-enantiomer and potent α1-adrenoceptor antagonist (Ki: α1a 6.51 nM, α1b 1.01 nM, α1d 1.97 nM).

Formula: C₁₉H₂₅N₅O₄

Purity: 98.96% - 99.79%

Color and Shape: Solid

Molecular weight: 387.43

Ref: TM-T12643

(R)-Terazosin

CAS: 109351-34-0

(R)-Terazosin

Formula: C₁₉H₂₅N₅O₄

Purity: ≥98%

Molecular weight: 387.43

Ref: 54-BUP09057

(R)-Terazosin

Controlled Product

CAS: 109351-34-0

Formula: C₁₉H₂₅N₅O₄

Color and Shape: Neat

Molecular weight: 387.43

Ref: TR-T105015

(R)-Terazosin

CAS: 109351-34-0

Terazosin is an alpha-adrenergic receptor antagonist that is used to treat benign prostatic hyperplasia, prostate cancer, and urinary incontinence. It is not a prodrug and does not have any active metabolites. Terazosin inhibits the binding of n-methyl-d-aspartic acid (NMDA) to its receptors in the central nervous system and may act as an NMDA antagonist. Terazosin also binds to soluble guanylate cyclase, which regulates nitric oxide production, leading to relaxation of smooth muscle cells in blood vessels. The drug has been shown to be effective in treating prostate cancer cells in vitro by inhibiting the growth of these cells at concentrations between 10 µM and 1 mM. Terazosin may inhibit the activity of long-term treatment with caco-2 cells at concentrations between 0.1 µM and 100 µM. Terazosin has been shown to bind ferrite at concentrations greater than 100

Formula: C₁₉H₂₅N₅O₄

Purity: Min. 95%

Molecular weight: 387.4 g/mol

Ref: 3D-JEA35134